SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Manit Munshi(Dana-Farber Cancer Institute), Guang Yang(Blueprint Medicines (United States)), Zachary R. Hunter(Harvard University), Christopher J. Patterson(Dana-Farber Cancer Institute), Cristina Jiménez(Central European Institute of Technology), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Maria Luisa Guerrera(Harvard University), Andrew Keezer(Dana-Farber Cancer Institute), Nickolas Tsakmaklis(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Sara J. Buhrlage(Harvard University), Steven P. Treon(Dana-Farber Cancer Institute), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Jinhua Wang(Harvard University), Xia Liu(Northwestern University), Nathanael S. Gray(Stanford University), Lian Xu(Huazhong Agricultural University), Jorge J. Castillo(Dana-Farber Cancer Institute)
Cited by 45
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k